| Date | Title | Description |
| 17.01.2026 | Proxima Secures $80M Seed Round to Redefine Drug Discovery | Proxima, an AI-native biotech firm, secured an $80 million seed funding round. DCVC led the investment. NVentures and other major investors participated. Formerly VantAI, the company now targets proximity therapeutics. It aims to revolution... |
| 14.01.2026 | Proxima: $80 Million Raised To Power The Next Generation Of Proximity-Based Medicines | Proxima, the AI-native biotech company developing drug discovery tools and therapeutics for proximity-based medicines, has raised an oversubscribed $80 million seed round and rebranded from VantAI as it sharpens its focus on proximity thera... |
| 13.01.2026 | Proxima Raises $80M in Seed Funding | Proxima (formerly VantAI), a NYC-based AI-native biotech company developing AI-driven drug discovery for proximity therapeutics, raised $80M in Seed funding.
The round was led by DCVC, with participation from NVentures (NVIDIA’s venture cap... |
| 15.12.2025 | Relation: Additional $26 Million Raised To Advance Lab In The Loop Drug Platform | Relation Therapeutics has raised an additional $26 million from existing investors NVentures, DCVC, and Magnetic Ventures as it continues building an AI-driven drug discovery and development platform focused on improving confidence in the u... |
| 18.10.2025 | Weave Bio Ignites AI Regulatory Revolution with $20M Funding | Weave Bio secured $20M in Series A funding, bringing total capital to $36M. This fuels its AI-native regulatory automation platform. It revolutionizes drug development, from lab to market. The investment targets global expansion, advanced A... |
| 17.10.2025 | Weave Bio Raises $20M in Series A Funding | Weave Bio, a San Francisco, CA-based provider of AI-native regulatory automation management solutions, raised $20m in Series A funding.
The round, which brought total capital raised to $36m, was led by USVP, with participation by Innovation... |
